Completion lymph node dissection after a positive sentinel node: No longer a must?

Current Opinion in Oncology

Volumn 25, Issue 2, 2013, Pages 152-159

  Van Der Ploeg, Augustinus P T ^a   Van Akkooi, Alexander C J ^a   Verhoef, Cornelis ^a   Eggermont, Alexander M M ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

completion lymph node dissection; melanoma; sentinel node; tumor load

Indexed keywords

CANCER PROGNOSIS; CANCER RISK; CANCER SIZE; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; HUMAN; LYMPH NODE DISSECTION; MELANOMA METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY;

HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84873735877     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835dafb4     Document Type: Review

References (107)

1. Neuhaus SJ, Clark MA, Thomas JM. Dr. Herbert Lumley Snow, MD, MRCS (1847-1930): the original champion of elective lymph node dissection in melanoma. Ann Surg Oncol 2004; 11:875-878.
2. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977; 297:627-630.
3. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982; 49:2420-2430.
4. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986; 61:697-705.
5. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998; 351:793-796.
6. Balch CM, Soong S, Ross MI, et al. Long-term results of a multiinstitutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7:87-97.
7. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224:255-263; discussion 263-266.
8. Lens MB, Dawes M, Goodacre T, Newton-Bishop JA. Elective lymph node dissection in patients with melanoma: systematic review and metaanalysis of randomized controlled trials. Arch Surg 2002; 137:458-461.
9. Hein DW, Moy RL. Elective lymph node dissection in stage I malignant melanoma: a meta-analysis. Melanoma Res 1992; 2:273-277.
10. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977; 39:456-466.
11. Morton DL, Wanek L, Nizze JA, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991; 214:491-499; discussion 499-501.
12. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
13. Nieweg OE, Estourgie SH. What is a sentinel node and what is a falsenegative sentinel node? Ann Surg Oncol 2004; 11 (3 Suppl.):169S-173S.
14. Thompson JF, Niewind P, Uren RF, et al. Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Res 1997; 7:500-506.
15. Kapteijn BA, Nieweg OE, Muller SH, et al. Validation of gamma probe detection of the sentinel node in melanoma. J Nucl Med 1997; 38:362-366.
16. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radio-lymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996; 223:217-224.
17. Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2012; 364:1738-1745.
18. Nieweg OE, Veenstra HJ. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2012; 365:570; author reply 571.
19. Thomas JM. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2012; 365:569-570; author reply 571.
20. De Giorgi V, Grazzini M, Massi D. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2012; 365:570-571; author reply 571.
21. Thomas JM. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 2008; 5:18-23.
22. Van Akkooi AC, de Wilt JH, Voit C, et al. Sentinel lymph-node false positivity in melanoma. Nat Clin Pract Oncol 2008; 5:E2.
23. Van Akkooi AC, Verhoef C, Eggermont AM. Importance of tumor load in the sentinel node in melanoma: clinical dilemmas. Nat Rev Clin Oncol 2010; 7:446-454.
24. Valsecchi ME, Silbermins D, de Rosa N, et al. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol 2011; 29:1479-1487.
25. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for earlystage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005; 242:302-311; discussion 311-313.
26. Mohrle M, Schippert W, Rassner G, et al. Is sentinel lymph node biopsy of therapeutic relevance for melanoma? Dermatology 2004; 209:5-13.
27. Gutzmer R, Al Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol 2005; 153:1137-1141.
28. Starz H, Balda BR. Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: a follow-up study of 148 patients. Int J Cancer 2007; 121:689-693.
29. Koskivuo I, Talve L, Vihinen P, et al. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Ann Surg Oncol 2007; 14:3566-3574.
30. Satzger I, Meier A, Hoy L, et al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Ann Surg Oncol 2011; 18:514-520.
31. Leiter U, Buettner PG, Bohnenberger K, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol 2010; 17:129-137.
32. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307-1317.
33. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: american society of clinical oncology and society of surgical oncology joint clinical practice guideline. J Clin Oncol 2012; 30:2912-2918.
34. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick ( or 1/2 4 mm) primary melanoma. Ann Surg Oncol 2000; 7:160-165.
35. Gershenwald JE, Coit DG, Sondak VK, Thompson JF. The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. Ann Surg Oncol 2012; 19:3301-3303.
36. Van der Ploeg AP, van Akkooi AC, Schmitz PI, et al. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. Eur J Cancer 2010.
37. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006; 24:4464-4471.
38. Kretschmer L, Beckmann I, Thoms KM, et al. Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas. Eur J Cancer 2005; 41:531-538.
39. Riber-Hansen R, Nyengaard JR, Hamilton-Dutoit SJ, Steiniche T. The nodal location of metastases in melanoma sentinel lymph nodes. Am J Surg Pathol 2009; 33:1522-1528.
40. Murali R, Thompson JF, Scolyer RA. Location of melanoma metastases in sentinel lymph nodes: what are the implications for histologic processing of sentinel lymph nodes in routine practice? Am J Surg Pathol 2010; 34:127-129; author reply 129-131.
41. Cochran AJ, Roberts A, Wen DR, et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours. Pathology 2004; 36:478-484.
42. Cook MG, Green MA, Anderson B, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200:314-319.
43. Scolyer RA, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 2008; 25:100-111.
44. Van Akkooi AC, de Wilt JH, Verhoef C, et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 2006; 42:372-380.
45. Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, Steiniche T. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer 2004; 100:1683-1691.
46. Scolyer RA,Murali R, Satzger I, Thompson JF. The detection and significance of melanoma micrometastases in sentinel nodes. Surg Oncol 2008; 17:165-174.
47. Spanknebel K, Coit DG, Bieligk SC, et al. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol 2005; 29:305-317.
48. Gietema HA, Vuylsteke RJ, de Jonge IA, et al. Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol 2004; 57:618-620.
49. Riber-Hansen R, Hastrup N, Clemmensen O, et al. Treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: a national multicentre study. Eur J Cancer 2011.
50. Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 2004; 17:747-755.
51. Debarbieux S, Duru G, Dalle S, et al. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol 2007; 157:58-67.
52. Dewar DJ, Newell B, Green MA, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 2004; 22:3345-3349.
53. Van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined rotterdam tumor load and dewar topography criteria. J Clin Oncol 2011; 29:2206-2214.
54. Govindarajan A, Ghazarian DM, McCready DR, Leong WL. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol 2007; 14:906-912.
55. Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 2004; 22:3677-3684.
56. McMasters KM, Wong SL, Edwards MJ, et al. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 2002; 9:137-141.
57. Scolyer RA, Li LX, McCarthy SW, et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol 2004; 122:532-539.
58. Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004; 11 (3 Suppl.):162S-168S.
59. Van Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (0.1 mm in sentinel nodes: are these nodes to be considered negative? Ann Oncol, 2006, 17, 1578-1585.
60. Vuylsteke RJ, Borgstein PJ, van Leeuwen PA, et al. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol 2005; 12:440-448.
61. Cadili A, Scolyer RA, Brown PT, et al. Total sentinel lymph node tumor size predicts nonsentinel node metastasis and survival in patients with melanoma. Ann Surg Oncol 2010.
62. Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 2008; 26:4296-4303.
63. Glumac N, Hocevar M, Zadnik V, Snoj M. Sentinel lymph node micrometastasis may predict nonsentinel involvement in cutaneous melanoma patients. J Surg Oncol 2008; 98:46-48.
64. Guggenheim M, Dummer R, Jung FJ, et al. The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma-a retrospective analysis of 392 cases. Br J Cancer 2008; 98:1922-1928.
65. Meier A, Satzger I, Volker B, et al. Comparison of classification systems in melanoma sentinel lymph nodes-an analysis of 697 patients from a single center. Cancer 2010; 116:3178-3188.
66. Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of nonsentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol 2010; 28:4441-4449.
67. Rossi CR, De Salvo GL, Bonandini E, et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol 2008; 15:1202-1210.
68. Satzger I, Volker B, Meier A, et al. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. Ann Surg Oncol 2008; 15:1723-1732.
69. Van Akkooi ACJ, Nowecki Z, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients. A multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008; 248:949-955.
70. Van der Ploeg IMC, Kroon BBR, Antonini N, et al. Comparison of three micromorphometreic pathology classifications of melanoma metastases in the sentinel node. Ann Surg 2009; 250:301-304.
71. Reeves ME, Delgado R, Busam KJ, et al. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 2003; 10:27-31.
72. Roka F, Mastan P, Binder M, et al. Prediction of nonsentinel node status and outcome in sentinel node-positive melanoma patients. Eur J Surg Oncol 2008; 34:82-88.
73. Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 2005; 201:37-47.
74. Pearlman NW, McCarter MD, Frank M, et al. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg 2006; 192:878-881.
75. Van Akkooi AC, Spatz A, Eggermont AM, et al. Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. Eur J Cancer 2009; 45:2736-2742.
76. Murali R, Cochran AJ, Cook MG, et al. Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. Cancer 2009; 115:5026-5037.
77. Starz H, Balda BR, Kramer KU, et al. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001; 91:2110-2121.
78. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28:2452-2459.
79. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
80. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM staging system for cutaneous melanoma.. and beyond. Ann Surg Oncol 2010; 17:1475-1477.
81. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
82. Murali R, Desilva C, Thompson JF, Scolyer RA. Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients. Ann Surg 2011.
83. Fink AM, Weihsengruber F, Duschek N, et al. Value of micromorphometric criteria of sentinel lymph node metastases in predicting further nonsentinel lymph node metastases in patients with melanoma. Melanoma Res 2011; 21:139-143.
84. Van der Ploeg IMC, Kroon BBR, Antonini N, et al. Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node? Ann Surg 2009; 249:1003-1007.
85. Fink AM, Weihsengruber F, Spangl B, et al. S-classification of sentinel lymph node biopsy predicts the results of complete regional lymph node dissection. Melanoma Res 2005; 15:267-271.
86. Bogenrieder T, van Dijk MR, Blokx WA, et al. No nonsentinel node involvement in melanoma patients with limited Breslow thickness and low sentinel node tumour load. Histopathology 2011; 59:318-326.
87. Baehner FL, Li R, Jenkins T, et al. The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival. Ann Surg Oncol 2012; 19:1034-1042.
88. Scheri RP, Essner R, Turner RR, et al. Isolated tumor cells in the sentinel node affect long-termprognosis of patients with melanoma. Ann Surg Oncol 2007; 14:2861-2866.
89. Ollila DW, Ashburn JH, Amos KD, et al. Metastatic melanoma cells in the sentinel node cannot be ignored. J Am Coll Surg 2009; 208:924-930.
90. Murali R, DeSilva C, McCarthy SW, et al. Sentinel lymph nodes containing very small 0.1 mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative, Ann Surg Oncol, 2012, 19, 1089-1099.
91. Pasquali S, Spillane AJ, de Wilt JH, et al. Surgeons' opinions on lymphadenectomy in melanoma patients with positive sentinel nodes: a worldwide web-based survey. Ann Surg Oncol 2012.
92. Henderson MA. Completion lymphadenectomy for melanoma patients with a positive sentinel node biopsy remains standard of care. Ann Surg Oncol 2006; 13:761-763.
93. McMasters KM. Why does no one want to perform lymph node dissection anymore? Ann Surg Oncol 2010; 17:358-361.
94. Kingham TP, Panageas KS, Ariyan CE, et al. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol 2010; 17:514-520.
95. Guggenheim MM, Hug U, Jung FJ, et al. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malginant melanoma. Ann Surg 2008; 247:687-693.
96. De Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. Eur J Surg Oncol 2006; 32:785-789.
97. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multiinstitutional study. Ann Surg Oncol 2006; 13:809-816.
98. Elias N, Tanabe KK, Sober AJ, et al. Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? Arch Surg 2004; 139:400-404; discussion 404-405.
99. Morton DL, Scheri RP, Balch CM. Can completion lymph node dissection be avoided for a positive sentinel node in melanoma? Ann Surg Oncol 2007; 14:2437-2439.
100. Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010; 17:3324-3329.
101. Van Akkooi AC, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol 2007; 33:102-108.
102. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 2003; 10:676-680.
103. Hughes TM, Thomas JM. Combined inguinal and pelvic lymph node dissection for stage III melanoma. Br J Surg 1999; 86:1493-1498.
104. De Vries M, Hoekstra HJ, Hoekstra-Weebers JE. Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma. Ann Surg Oncol 2009; 16:2840-2847.
105. Van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. Br J Surg 2012; 99:1396-1405.
106. Nowecki ZI, Rutkowski P, Michej W. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4mm (pT2-pT3). Ann Surg Oncol 2008; 15:2223-2234.
107. Kunte C, Geimer T, Baumert J, et al. Analysis of predictive factors for the outcome of complete lymph node dissection in melanoma patients with metastatic sentinel lymph nodes. J Am Acad Dermatol 2011; 64:655-662.